Isoflurane pp 304-310 | Cite as

Isoflurane and Malignant Hyperthermia

  • W. Mauritz
  • H. Gilly
  • P. Sporn
  • K. Steinbereithner
  • M. Weindlmayr-Göttel
Conference paper
Part of the Anaesthesiology Intensive Care Medicine/Anaesthesiologie und Intensivmedizin book series (A+I, volume 182)


Unexpected fever during or following anesthesia associated with death of the patient has been reported several times since the beginning of this century, but it was Denborough and Lovell [6] who in 1960 recognized the genetic nature of malignant hyperthermia (MH). The following years witnessed a blossoming of research into the diagnosis, treatment, genetic, and biochemical nature of MH. All potent inhalation anesthetics as well as succinylcholine were identified as possible triggering agents. By far the most crises have been reported with halothane because it has been available for 30 years, but there are also case reports of MH associated with isoflurane [3,9] and enflurane [5] anesthesia. In vitro contracture tests using halothane and caffeine are an essential part of our MH family screening program, which was started in 1976 and now contains the records of 230 investigated individuals. Following the introduction of isoflurane into clinical practice 2 years ago it seemed reasonable to compare the trigger effects of halothane and isoflurane in vitro.


Muscle Tension Volatile Anesthetic Malignant Hyperther Malignant Hyperthermia Adenylate Kinase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Britt BA (1982) Malignant hyperthermia: a review. In: Milton AS (ed) Pyretics and antipyretics. Springer, Berlin Heidelberg New York, pp 547–615 (Handbook of experimental pharmacology, vol 60 )Google Scholar
  2. 2.
    Britt BA, Endrenyi L, Frodis W, Scott E, Kalow W (1980) Comparison of effects of several inhalation anaesthetics on caffeine-induced contractures of normal and malignant hyperthermic skeletal muscle. Can Anaesth Soc J 27: 12–15PubMedCrossRefGoogle Scholar
  3. 3.
    Boheler J, Hamrick JC, McKnight RL, Eger EI II (1982) Isoflurane and malignant hyperthermia. Anesth Analg 61: 712–713PubMedCrossRefGoogle Scholar
  4. 4.
    Brückner BJ (1985) Isoflurane: Ergebnisse klinischer Untersuchungen und wesentliche Indikationen der Anwendung. In: Bergmann H, Fitzal S, Steinbereithner K, Wiethoff EO, Zimpfer M (eds) Beiträge zur Anaesthesiologie und Intensivmedizin, vol 14: Isofluran - Standort und Perspektiven. Maudrich, Wien pp 147–173Google Scholar
  5. 5.
    Caropreso PR, Gittleman MA, Reilly DJ, Patterson LT (1975) Malignant hyperthermia associated with enflurane anesthesia. Arch Surg 110: 1491–1493PubMedGoogle Scholar
  6. 6.
    Denborough MA, Lovell RRH (1960) Anaesthetic deaths in a family. Lancet 11: 45CrossRefGoogle Scholar
  7. 7.
    European Malignant Hyperpyrexia Group (1984) A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 56: 1267–1269Google Scholar
  8. 8.
    Ilias WK, Williams CH, Fulfer RT, Dozier SE (1985) Diltiazem inhibits halothane-induced contractions in malignant hyperthermia-susceptible muscles in vitro. Br J Anaesth 57: 994–995PubMedCrossRefGoogle Scholar
  9. 9.
    Joseph MM, Shah K, Viljoen JF (1982) Malignant hyperthermia associated with isoflurane anesthesia. Anesth Analg 61: 711–712PubMedCrossRefGoogle Scholar
  10. 10.
    Kemmotsu O, Hashimoto Y, Shimosato S (1973) Inotropic effects of isoflurane on mechanics of contraction in isolated cat papillary muscles from normal and failing hearts. Anesthesiology 39: 470–477PubMedCrossRefGoogle Scholar
  11. 11.
    Leslie GC, MacLachlan DC (1976) Comments on isometric twitch tension responses of human muscle biopsy challenged in vitro with caffeine and halothane. Br J Anaesth 48: 1122Google Scholar
  12. 12.
    Reed SB, Strobel GE (1978) An in-vitro model of malignant hyperthermia: differential effects of inhalational anesthetics on caffeine-induced muscle contratures. Anesthesiology 48: 254–259PubMedCrossRefGoogle Scholar
  13. 13.
    Renzi F, Waud BE (1977) Partition coefficients of volatile anesthetics in Krebs solution Anesthesiology 47: 62–63PubMedCrossRefGoogle Scholar
  14. 14.
    Sachsenheimer W, Pai EF, Schulz GE, Schirmer RH (1977) Halothane binds in the adenine-specific niche of crystalline adenylate kinase. FEBS Lett 79: 310–312PubMedCrossRefGoogle Scholar
  15. 15.
    Schmidt K, Heller W (1977) The metabolic disarrangement of malignant hyperpyrexia - a consequence of a disturbed membrane transport. Hoppe-Seyler’s Z Physiol Chem 358: 301CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • W. Mauritz
  • H. Gilly
  • P. Sporn
  • K. Steinbereithner
  • M. Weindlmayr-Göttel

There are no affiliations available

Personalised recommendations